Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Rhythm Pharmaceuticals Inc

Healthcare US RYTM

87.43USD
2.72(3.21%)

Last update at 2026-06-04T17:47:00Z

Day Range

85.0587.44
LowHigh

52 Week Range

15.5052.57
LowHigh

Fundamentals

  • Previous Close 84.71
  • Market Cap2207.83M
  • Volume119869
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-270.00701M
  • Revenue TTM91.93M
  • Revenue Per Share TTM1.57
  • Gross Profit TTM 21.50M
  • Diluted EPS TTM-4.63

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -181.11900M -69.61200M -133.99600M -140.72900M -74.06400M
Minority interest - - - - -
Net income -183.08100M -68.00700M -130.72700M -134.62400M -74.06400M
Selling general administrative 92.03M 68.49M 46.12M 36.55M 28.08M
Selling and marketing expenses - - - - -
Gross profit 21.50M 2.56M - - 0.00000M
Reconciled depreciation 1.67M 1.16M 0.69M 0.83M 0.44M
Ebit -179.15700M -171.21700M -137.26500M -146.83400M -78.85900M
Ebitda -175.91800M -170.05900M -136.57500M -146.00000M -78.41700M
Depreciation and amortization 3.24M 1.16M 0.69M 0.83M 0.44M
Non operating income net other 3.24M 100.45M 2.58M 5.27M 4.35M
Operating income -179.15700M -170.05900M -136.57500M -146.00000M -78.41700M
Other operating expenses 202.79M 173.21M 136.57M 146.00M 78.42M
Interest expense 5.20M 100.45M 0.00000M 0.00000M 0.00000M
Tax provision - 0.00000M - - -
Interest income 4.03M 0.45M 2.58M 5.27M 4.35M
Net interest income -1.17200M 0.45M 2.58M 5.27M 4.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.96M -1.60500M -3.26900M -6.10500M 4.35M
Total revenue 23.64M 3.15M 0.00000M 0.00000M 0.00000M
Total operating expenses 200.66M 172.61M 136.57M 146.00M 78.42M
Cost of revenue 2.13M 0.60M - - 0.00000M
Total other income expense net -1.96200M 100.45M 2.58M 5.27M 4.35M
Discontinued operations - - - - -
Net income from continuing ops -181.11900M -69.61200M -133.99600M -140.72900M -74.06400M
Net income applicable to common shares -181.11900M -69.61200M -133.99600M -140.72900M -74.06400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 332.75M 382.48M 329.52M 187.07M 308.52M
Intangible assets 7.03M 7.88M 4.66M - -
Earning assets - - - - -
Other current assets 6.67M 11.81M 12.51M 8.88M 9.95M
Total liab 162.99M 118.22M 45.37M 20.55M 27.50M
Total stockholder equity 169.76M 264.26M 284.15M 166.53M 281.02M
Deferred long term liab - 75.81M - - -
Other current liab 48.26M 32.89M 30.08M 0.18M 0.38M
Common stock 0.06M 0.06M 0.05M 0.04M 0.04M
Capital stock 0.06M 0.06M 0.05M 0.04M 0.04M
Retained earnings -894.73600M -710.05800M -528.93900M -459.32700M -325.33100M
Other liab - 77.15M - - -
Good will - - - - -
Other assets - 16.98M 12.14M 2.21M 0.40M
Cash 60.08M 127.68M 59.25M 100.85M 62.29M
Cash and equivalents - - - - -
Total current liabilities 55.20M 39.81M 43.43M 17.99M 24.42M
Current deferred revenue 1.29M 1.43M 7.00M 12.38M 13.15M
Net debt -58.82100M -125.73300M -56.69700M -97.76800M -58.73600M
Short term debt 0.77M 0.68M 0.61M 0.54M 0.47M
Short long term debt - - - - -
Short long term debt total 1.26M 1.94M 2.55M 3.09M 3.56M
Other stockholder equity 1064.30M 974.36M 813.04M 625.76M 606.31M
Property plant equipment - 2.20M 2.81M 3.19M 5.72M
Total current assets 308.27M 354.24M 308.39M 181.67M 302.40M
Long term investments - 16.66M 11.81M - -
Net tangible assets - 256.38M 279.49M 166.53M 281.02M
Short term investments 215.76M 205.61M 235.61M 71.94M 230.16M
Net receivables 14.87M 6.22M 1.02M - -
Long term debt - 1.34M - - -
Inventory 8.62M 2.92M 0.11M - -
Accounts payable 4.88M 4.80M 5.74M 4.90M 10.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.13M -0.09200M -0.00100M 0.05M -0.75200M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.05M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - -710.05800M -528.93900M -459.32700M -325.33100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 15.33M 16.98M 12.14M 0.40M 0.40M
Deferred long term asset charges - - - - -
Non current assets total 24.48M 28.25M 21.14M 5.41M 6.12M
Capital lease obligations 1.26M 1.94M 2.55M 3.09M 3.56M
Long term debt total - 1.34M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 32.31M -163.72500M 158.75M -24.58500M -86.42600M
Change to liabilities -5.06300M 18.31M -6.44600M 10.51M 6.95M
Total cashflows from investing activities 28.03M -62.15900M 158.53M -27.97000M -87.14800M
Net borrowings 72.34M - - - -
Total cash from financing activities 213.83M 166.48M 2.01M 163.47M 164.69M
Change to operating activities -6.65600M -16.41500M 0.55M -5.44000M -6.28600M
Net income -181.11900M -69.61200M -133.99600M -140.72900M -74.06400M
Change in cash 68.43M -41.68100M 38.56M 12.75M 15.48M
Begin period cash flow 59.58M 101.26M 62.70M 49.94M 34.46M
End period cash flow 128.00M 59.58M 101.26M 62.70M 49.94M
Total cash from operating activities -173.42800M -146.00300M -121.98000M -122.75000M -62.05600M
Issuance of capital stock 131.11M 161.73M 0.00000M 161.35M 162.88M
Depreciation 1.67M 1.16M 0.69M 0.83M 0.44M
Other cashflows from investing activities -4.00000M 102.00M 95.00M -24.58500M -86.42600M
Dividends paid - - - - -
Change to inventory -2.80600M -0.01100M -0.01100M -0.01100M -
Change to account receivables -5.19900M -1.25000M -1.25000M -1.25000M -
Sale purchase of stock 141.49M 166.48M 2.01M 163.47M 164.69M
Other cashflows from financing activities 82.72M 4.75M -159.34300M 2.12M 1.81M
Change to netincome 20.35M 20.55M 17.22M 11.88M 6.39M
Capital expenditures 4.28M 5.43M 0.21M 3.38M 0.72M
Change receivables -5.19900M - - - -
Cash flows other operating 0.41M -115.25700M 0.55M -5.23700M -1.77700M
Exchange rate changes - - - - -
Cash and cash equivalents changes 68.43M -41.68100M 38.56M 12.75M 15.48M
Change in working capital -19.72400M 1.90M -5.89500M 5.07M 0.67M
Stock based compensation 19.83M 20.80M 17.45M 11.88M 6.39M
Other non cash items 5.91M -0.25000M -0.23400M 0.20M 4.51M
Free cash flow -177.70900M -151.43700M -122.19400M -126.13500M -62.77800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RYTM
Rhythm Pharmaceuticals Inc		 2.72 3.21% 87.43 - - 31.33 14.29 27.78 -12.7676
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals Inc

222 Berkeley Street, Boston, MA, United States, 02116

Key Executives

Name Title Year Born
Dr. David P. Meeker M.D. Chairman, Pres & CEO 1954
Mr. Hunter C. Smith M.B.A. CFO & Treasurer 1969
Mr. Joseph Shulman Chief Technical Officer 1975
Mr. Yann Mazabraud Exec. VP & Head of International 1973
Ms. Jennifer L. Chien Exec. VP & Head of North America 1975
Mr. William T. Roberts Chief Accounting Officer 1979
Mr. David Connolly Head of Investor Relations & Corp. Communications NA
Mr. Jim Flaherty Sr. VP & Gen. Counsel NA
Ms. Sarah Ryan VP of Sales & Marketing NA
Ms. Pamela J. Cramer Chief HR Officer 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.